$13.50
-0.32 (-2.32%)
Open$13.87
Previous Close$13.82
Day High$13.94
Day Low$13.25
52W High$18.57
52W Low$7.48
Volume—
Avg Volume1.87M
Market Cap2.17B
P/E Ratio—
EPS$-5.67
SectorBiotechnology
Analyst Ratings
Strong Buy
25 analysts
Price Target
+122.7% upside
Current
$13.50
$13.50
Target
$30.06
$30.06
$17.22
$30.06 avg
$35.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 166.56M | 159.79M | 165.80M |
| Net Income | 26.40M | 27.52M | 28.79M |
| Profit Margin | 15.9% | 17.2% | 17.4% |
| EBITDA | 53.49M | 47.96M | 56.14M |
| Free Cash Flow | 17.32M | 22.87M | 17.57M |
| Rev Growth | +0.5% | -2.4% | +23.6% |
| Debt/Equity | 0.62 | 0.47 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |